Arthralgias and myalgias related to quinupristin-dalfopristin administration

被引：42

作者：

Olsen, KM

Rebuck, JA

Rupp, ME

机构：

[1] Univ Nebraska, Med Ctr, Coll Pharm, Dept Pharm Practice, Omaha, NE 68198 USA

[2] Univ Nebraska, Med Ctr, Coll Med, Dept Internal Med, Omaha, NE 68198 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2001年 / 32卷 / 04期

关键词：

D O I：

10.1086/318702

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.

引用

收藏

页码：E83 / E86

页数：4

相关论文

共 9 条

[1]

FAGON JY, 1997, 20 INT C CHEM ICC SY, P44

[2] Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections [J].

Moellering, RC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 :25-30

[3] The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium [J].

Moellering, RC ;

Linden, PK ;

Reinhardt, J ;

Blumberg, EA ;

Bompart, F ;

Talbot, GH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :251-261

[4] Vancomycin-resistant enterococci [J].

Murray, BE .

AMERICAN JOURNAL OF MEDICINE, 1997, 102 (03) :284-293

[5] Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin [J].

Nichols, RL ;

Graham, DR ;

Barriere, SL ;

Rodgers, A ;

Wilson, SE ;

Zervos, M ;

Dunn, DL ;

Kreter, B .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :263-273

[6] Prospective, randomized dose-ranging open phase II pilot study of quinupristin dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia [J].

Raad, I ;

Bompart, F ;

Hachem, R .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (03) :199-202

[7] Safety and tolerability of quinupristin/dalfopristin: administration guidelines [J].

Rubinstein, E ;

Prokocimer, P ;

Talbot, GH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 :37-46

[8]

TALBOT GH, 1997, 20 INT C CHEM ICC SY, P44

[9]

1999, MED LETT DRUGS THER, V41, P109